文献速递抗栓抗凝管理药物不良反应与药物警戒

静脉血栓栓塞症延长口服抗凝治疗的有效性与安全性:回顾性队列研究

Effectiveness and Safety of Extended Oral Anticoagulant Therapy in Patients with Venous Thromboembolism: A Retrospective Cohort Study.
PubMed 文献 · Clin Pharmacol Ther · 2022-05-02

本研究基于MarketScan数据库(2013-2019)开展回顾性队列研究,比较静脉血栓栓塞症患者完成6个月初始治疗后,接受阿哌沙班、华法林或不延长治疗复发VTE及大出血的风险。共纳入14,818例患者,结果显示阿哌沙班和华法林均降低复发VTE风险,但华法林增加大出血风险,阿哌沙班安全性更优。

要点

  • 与不延长治疗相比,阿哌沙班降低复发VTE风险(HR 0.10,95%CI 0.04-0.26)且不增加大出血风险。
  • 与不延长治疗相比,华法林降低复发VTE风险(HR 0.23,95%CI 0.12-0.44)但增加大出血风险(HR 2.64,95%CI 1.51-4.59)。
  • 与华法林相比,阿哌沙班降低大出血风险(HR 0.42,95%CI 0.22-0.80),复发VTE风险无差异。

核心结论

  • 在真实临床环境中,延长抗凝治疗使用阿哌沙班或华法林均与复发VTE风险降低相关,且阿哌沙班相比华法林大出血事件更少。

研究设计与样本

  • 使用MarketScan Commercial and Medicare Supplemental数据库(2013-2019)的回顾性队列研究。
  • 纳入完成6个月初始治疗并接受延长口服抗凝治疗(阿哌沙班、华法林)或无延长治疗的VTE患者,共14,818例。
  • 采用Cox比例风险模型结合逆概率治疗加权估计风险比(HR)及95%置信区间(CI)。

主要发现

  • 阿哌沙班组4,338例,华法林组5,298例,无延长治疗组5,182例。
  • 与无延长治疗相比,阿哌沙班降低复发VTE风险(HR 0.10,95%CI 0.04-0.26),不增加大出血风险(HR 1.06,95%CI 0.52-2.17)。
  • 与无延长治疗相比,华法林降低复发VTE风险(HR 0.23,95%CI 0.12-0.44),但增加大出血风险(HR 2.64,95%CI 1.51-4.59)。
  • 与华法林相比,阿哌沙班降低大出血风险(HR 0.42,95%CI 0.22-0.80),复发VTE风险无差异(HR 0.46,95%CI 0.15-1.36)。

临床怎么用

  • 对于完成6个月初始治疗的VTE患者,延长抗凝治疗可考虑阿哌沙班以降低复发VTE风险且不增加大出血风险。
  • 若选用华法林进行延长抗凝,需密切监测大出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Limited real-world evidence exists for effectiveness and safety of extended oral anticoagulation beyond 6 months of initial treatment in prevention of recurrent venous thromboembolism (VTE) and adverse major bleeding events among patients with VTE. Using MarketScan Commercial and Medicare Supplemental databases (2013-2019), we conducted a retrospective cohort study to compare the risk of recurrent VTE and major bleeding events during extended treatment among patients with VTE who completed the 6-month initial treatment and received extended oral anticoagulant treatment with apixaban, warfarin, or no extended treatment. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazards modeling with inverse probability treatment weighting. We identified 14,818 patients with extended treatment of apixaban (n = 4,338), warfarin (n = 5,298), or no extended treatment (n = 5,182). Compared with no extended treatment, apixaban use was associated with decreased risk of recurrent VTE (HR: 0.10, 95% CI: 0.04-0.26) without increased risk of major bleeding events (HR: 1.06, 95% CI: 0.52-2.17); warfarin use was associated with decreased risk of recurrent VTE (HR: 0.23, 95% CI: 0.12-0.44) but with increased risk of major bleeding events (HR: 2.64, 95% CI: 1.51-4.59). Compared with warfarin, apixaban use was associated with decreased risk of major bleeding events (HR: 0.42, 95% CI: 0.22-0.80) but no difference in risk of recurrent VTE (HR: 0.46, 95% CI: 0.15-1.36). In a real-world clinical setting, extended anticoagulation with apixaban or warfarin was associated with decreased risk of recurrent VTE compared with no extended treatment, and apixaban had a better safety profile with fewer major bleeding events compared with warfarin among commercially insured patients with VTE.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kang HR, Lo-Ciganic WH, DeRemer CE, et al. Effectiveness and Safety of Extended Oral Anticoagulant Therapy in Patients with Venous Thromboembolism: A Retrospective Cohort Study. Clin Pharmacol Ther. 2022. PMID: 35420702. doi:10.1002/cpt.2611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。